Skip to main content
Fig. 2 | Acta Neuropathologica Communications

Fig. 2

From: Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study

Fig. 2

Plasmatic expression of MMP9 is specific for glioblastoma. A Patient characteristics of peri-operative cohort. B Plasmatic expression of MMP2 and MMP9 before surgical resection of newly-diagnosed glioblastoma or cerebral aneurysm and in healthy controls. C MMP2 and MMP9 plasma level before and after glioblastoma resection. D MMP2 and MMP9 plasma level before and after cerebral aneurysm resection. MMP9 is highly expressed into glioblastoma and significantly decreases after tumor resection. *p < 0.05; **p < 0.01; ***p < 0.001

Back to article page

Acta Neuropathologica Communications

ISSN: 2051-5960

Contact us